Genentech and 23andMe have partnered on a new breast cancer research initiative through the Web to better understand how genetics play a role in how some people respond to a certain metastatic breast cancer treatment.
You are InVited
The InVite study aims to enroll 1,000 individuals with metastatic breast cancer who received a certain medicine in 2010 and/or 2011. For more information about this study, and to sign up, visit http://www.23andme.com/invite-study
What You Get For Participating
• Convenient and easy opportunity to participate in new type of research
• Help advance medical research in metastatic breast cancer and its treatment
• Receive updates about research progress and discoveries
• Learn about your health and ancestry through FREE access to 23andMe's Personal Genome Service
Questions? Email project-help@23andme.com.